skip to primary navigation skip to content
Loading Events

Upcoming Events

Events Search and Views Navigation

Event Views Navigation

September 2019

Lunchtime Walk

September 24 @ 12:00 pm - 12:30 pm
|Recurring Event (See all)

An event every week that begins at 12:00 pm on Tuesday, repeating until April 6, 2027

An event every week that begins at 1:30 pm on Tuesday, repeating until April 6, 2027

Addenbrooke’s Main Entrance, Cambridge Biomedical Campus
Cambridge, Cambridge CB2 0QQ United Kingdom
+ Google Map

Every Tuesday members of the School of Clinical Medicine and the NHS join together  for a 30-minute lunchtime walk around the Biomedical Campus and surrounding areas (including Nightingale park and Great Kneighton park).   These walks take place every Tuesday at 12pm and 1.30pm   Meet by the main reception near the entrance to the Concourse   Walks are open to everyone on campus and are led by Sustrans volunteers (  

Find out more »

TET-family dioxygenases, immune responses and cancer – Anjana Rao, La Jolla Institute for Allergy and Immunology

September 26 @ 1:00 pm - 2:00 pm

In 2009, our lab reported that enzymes of the TET (Ten-Eleven Translocation) family were a new class of epigenetic regulators that altered the modification status of cytosine bases in DNA. The three mammalian TET enzymes – TET1, TET2 and TET3 – successively oxidize the methyl group of 5-methylcytosine (5mC) to yield 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). These modified cytosine bases (together termed oxidized methylcytosines, oxi-mC) facilitate DNA demethylation and are also novel epigenetic marks. DNA methylation has long…

Find out more »

October 2019

‘Activation of transcription factor Nrf2 as a strategy to restore the cellular redox and protein homeostasis’ – Professor Albena Dinkova-Kostova,Jacqui Wood Cancer Centre, Division of Cellular Medicine, University of Dundee

Disrupted redox and protein homeostasis and chronic inflammation are characteristic features of most human pathologies. The transcription factor Nrf2 regulates the expression of large networks of genes encoding proteins that provide powerful and long-lasting protection against damage by oxidants and pro-inflammatory agents. Most pharmacological activators of Nrf2 (termed inducers) are electrophiles that target discreet highly reactive sensor cysteines within Kelch-like ECH-associated protein 1 (Keap1), the main negative regulator of Nrf2, impairing the repressor function of Keap1, and allowing for Nrf2…

Find out more »

LMB Seminar Series – Kendrew Lecture – How a ubiquitin-like protein brings ubiquitylation to life – Brenda Schulman, Director at the Max Planck Institute of Biochemistry

Abstract to follow

Find out more »

Postdoc’s Biomedical Campus Pub Night

October 10 @ 6:30 pm - 9:30 pm
|Recurring Event (See all)

An event every month that begins at 6:30 pm on day Second of the month, repeating indefinitely

Frank Lee Centre, Hills Road
Cambridge, CB2 0SN
+ Google Map

Dear Postdocs from the south side of the city! Has your experiment not worked and you would like to forget about it? Has your experiment worked brilliantly and you would like to celebrate? Or are you just eager to meet some postdocs outside of your own lab? Whatever your reason, come and join the postdocs from the Addenbrooke's campus for a pub night. Have a drink, relax, chat and make new friends. The pub we will be going to is…

Find out more »

Transcriptional dependencies in cancer – Christopher Vakoc, Cold Spring Harbor Laboratory

October 11 @ 1:00 pm - 2:00 pm

A reprogrammed transcriptional state is required for malignant transformation, a process that can render cancer cells addicted to specific transcriptional regulators. Our research focuses on identifying transcriptional addictions in cancer using genetic screens, followed by a deep investigation of underlying mechanisms. Over several years, our studies have reinforced the role of sequence-specific DNA binding transcription factors as the premier transcriptional addictions deserving of therapeutic intervention, such as MYB in acute myeloid leukemia and POU2F3 in small cell lung cancer. However,…

Find out more »
+ Export Events